Kinch starts with an overview of the history of pharmaceutical introduction to the U.S. marketplace,

Home Articles Application Notes News White Papers Global Funding Forecast Topics General Sciences down s syndrome Materials Manufacturing Energy Environment Life Sciences Information Technologies Policy/Regulations Lab Operations New to Market Emerging Technologies Business of Innovation All Topics Products Product down s syndrome Directory Analysis Instruments Chemicals and Biochemicals down s syndrome Chromatography Systems Computer Hardware and Software Electronic Components Lab Equipment Laboratory Building/Design Manufacturing Systems Materials, Gases and Standards Mechanical Devices Meters and Monitors Microscopes, down s syndrome Imaging and Lasers Services Spectrometry and Spectroscopy Testing Systems Vacuum Systems Awards R&D 100 Awards Innovator of the Year Scientist of the Year Laboratory of the Year Resources R&D down s syndrome 100 Archive down s syndrome Company Directory Add Your Company R&D Magazine Archive Laboratory Design News Blogs Multimedia Events Free Subscriptions
Yale Univ. s Michael down s syndrome Kinch spent his spare time in the last year creating a massive database that encompasses the entire history of drug development in the U.S. In a series of 20 articles scheduled to be published over the next year in Drug Discovery Today , Kinch mines the data and provides historical tidbits about the history of drug development and reveals trends on how or whether we will get new medicines in the future.
The hope is that this data such as when and what drugs were approved, what happened down s syndrome to companies that developed them, who did the clinical trials will convey insight into trends that today are reshaping the biopharmaceutical industry, said Kinch, managing director of the Yale Center for Molecular Discovery at West Campus.
Kinch starts with an overview of the history of pharmaceutical introduction to the U.S. marketplace, beginning in 1827 when morphine was introduced by the German company down s syndrome Merck. Aspirin, which made its debut in 1899, was the perhaps the first blockbuster drug, notes Kinch. The heart of the series, down s syndrome however, centers down s syndrome on the analyses of 1453 new drugs granted approval since the passage of the Food and Drug Act of 1906.
For instance, the second paper in the series, shows that the contributions of biotechnology companies to new drug development has been declining since 2000 and is at a level not seen since the early 1980s. Pharmaceutical companies now swallow up biotechnology organizations even before a company gains its first FDA approval, the analyses shows.
Future papers examine other trends. For instance, the rates of approvals for drugs that combat HIV are declining at a rate that mimics the decline of approvals for new antibiotics 20 years ago. That deficit left the medical industry ill-prepared to deal with the rise of antibiotic-resistant bacteria and so may suggest the emergence down s syndrome of future problems with drug-resistant down s syndrome HIV, contends Kinch.
Search
View More Product Releases
Advertisement
Bioscience Technology Chromatography Techniques Drug Discovery & Development Lab Design News Laboratory Equipment Pharmaceutical Processing Scientific Computing